These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 1833451)

  • 1. Differential T cell hyporesponsiveness induced by in vivo administration of intact or F(ab')2 fragments of anti-CD3 monoclonal antibody. F(ab')2 fragments induce a selective T helper dysfunction.
    Hirsch R; Archibald J; Gress RE
    J Immunol; 1991 Oct; 147(7):2088-93. PubMed ID: 1833451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contrasting in vivo effects on T helper cell functions induced by mitogenic (intact) versus nonmitogenic (F(ab')2) anti-CD3 monoclonal antibody.
    Sawchuk SS; Gates R; Hirsch R
    Transplantation; 1995 Dec; 60(11):1331-7. PubMed ID: 8525530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.
    Hirsch R; Gress RE; Pluznik DH; Eckhaus M; Bluestone JA
    J Immunol; 1989 Feb; 142(3):737-43. PubMed ID: 2521507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valency of CD3 binding and internalization of the CD3 cell-surface complex control T cell responses to second signals: distinction between effects on protein kinase C, cytoplasmic free calcium, and proliferation.
    Ledbetter JA; June CH; Martin PJ; Spooner CE; Hansen JA; Meier KE
    J Immunol; 1986 Jun; 136(11):3945-52. PubMed ID: 3084650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells.
    Tutt A; Stevenson GT; Glennie MJ
    J Immunol; 1991 Jul; 147(1):60-9. PubMed ID: 1675655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo administration of anti-CD3 monoclonal antibodies or immunotoxins in murine recipients of allogeneic T cell-depleted marrow for the promotion of engraftment.
    Blazar BR; Hirsch R; Gress RE; Carroll SF; Vallera DA
    J Immunol; 1991 Sep; 147(5):1492-503. PubMed ID: 1831826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion.
    Carteron NL; Schimenti CL; Wofsy D
    J Immunol; 1989 Mar; 142(5):1470-5. PubMed ID: 2521880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ cells.
    Carteron NL; Wofsy D; Seaman WE
    J Immunol; 1988 Feb; 140(3):713-6. PubMed ID: 2448372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69.
    Woods M; Guy R; Waldmann H; Glennie M; Alexander DR
    Cell Immunol; 1998 May; 185(2):101-13. PubMed ID: 9636688
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 x anti-tumor F(ab')2 bifunctional antibody activates and retargets tumor-infiltrating lymphocytes.
    Chapoval AI; Nelson H; Thibault C
    J Immunol; 1995 Aug; 155(3):1296-303. PubMed ID: 7636196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of T cells by cross-linking an anti-CD3 antibody with a second anti-T cell antibody: mechanism and subset-specific activation.
    Walker C; Bettens F; Pichler WJ
    Eur J Immunol; 1987 Jun; 17(6):873-80. PubMed ID: 2439351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of IL-2 production by activation of T cells through Ly-6A/E.
    Codias EK; Rutter JE; Fleming TJ; Malek TR
    J Immunol; 1990 Sep; 145(5):1407-14. PubMed ID: 2143518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells.
    Yoshizawa H; Chang AE; Shu SY
    Cancer Res; 1992 Mar; 52(5):1129-36. PubMed ID: 1531321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct activation of murine resting T cells by con A or anti-CD3 Ig.
    Quintáns J; Yokoyama A; Evavold B; Hirsch R; Mayforth RD
    J Mol Cell Immunol; 1989; 4(4):225-35; discussion 235-7. PubMed ID: 2532886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of T helper cell hyporesponsiveness in an experimental model of autoimmunity by using nonmitogenic anti-CD3 monoclonal antibody.
    Hughes C; Wolos JA; Giannini EH; Hirsch R
    J Immunol; 1994 Oct; 153(7):3319-25. PubMed ID: 8089501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
    J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmitogenic anti-CD3F(ab')2 fragments inhibit lethal murine graft-versus-host disease induced across the major histocompatibility barrier.
    Blazar BR; Taylor PA; Snover DC; Bluestone JA; Vallera DA
    J Immunol; 1993 Jan; 150(1):265-77. PubMed ID: 8417127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen-induced IL-2 production and proliferation at defined stages of T helper cell development.
    Chang JF; Thomas CA; Kung JT
    J Immunol; 1991 Aug; 147(3):860-6. PubMed ID: 1830601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional and systemic distribution of anti-tumor x anti-CD3 heteroaggregate antibodies and cultured human peripheral blood lymphocytes in a human colon cancer xenograft.
    Nelson H; Ramsey PS; Kerr LA; McKean DJ; Donohue JH
    J Immunol; 1990 Nov; 145(10):3507-15. PubMed ID: 1700013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.